周邊藥物釋放型球囊擴張導管市場（依藥物類型、球囊長度、塗層技術及最終用戶分類）－2026-2032年全球預測

2025 年外周藥物釋放型球囊擴張導管市場價值為 8.6301 億美元，預計到 2026 年將成長至 9.4996 億美元，年複合成長率為 10.69%，到 2032 年將達到 17.5784 億美元。

關鍵市場統計數據
基準年 2025	8.6301億美元
預計年份：2026年	9.4996億美元
預測年份 2032	1,757,840,000 美元
複合年成長率 (%)	10.69%

周邊動脈評分藥物釋放型球囊擴張導管的全面實施：臨床作用、技術基礎及相關人員影響

末梢用刻痕藥物釋放型球囊擴張導管融合了介入技術和標靶藥物傳遞技術，為臨床醫生治療複雜的周邊動脈疾病提供了新的選擇。這些裝置結合了機械性斑塊修飾和局部抗增殖藥物給藥，可改善血管準備並維持通暢性，尤其適用於簡單球囊血管成形術難以處理的複雜病變。隨著臨床團隊不斷最佳化患者選擇和手術流程，這些導管在血管外科醫生、介入放射科醫生和導管檢查室工作人員參與的多學科討論中發揮著日益重要的作用。

重塑周邊血管刻痕藥物釋放型球囊應用的變革性變化分析：包括手術技術、材料科學和臨床路徑

周邊血管刻痕藥物釋放型球囊治療領域正經歷一系列變革，這些變革的驅動力來自臨床證據、材料科學和手術最佳化。臨床上，對複雜病變亞型的不斷積累，使人們對刻痕機制何時比傳統血管成形術更具價值，以及藥物釋放型何時能顯著預防血管再阻塞有了更深入的了解。因此，通訊協定的製定和操作者的技術也隨之發展，更加注重病變準備、球囊尺寸的選擇以及在條件允許的情況下進行血管內影像學檢查後的擴張評估。

評估2025年美國關稅對周邊刻痕藥物洗脫球囊的供應鏈、成本和策略採購的累積影響

2025年美國關稅政策為依賴跨境供應鏈的周邊血管器材製造商、經銷商和醫療系統引入了新的策略因素。雖然關稅本身不會改變器材的臨床特性，但它會影響最終到岸成本、供應商選擇和庫存策略，從而改變採購策略。為此，各機構正在重新評估供應商多元化和物流模式，以降低關稅相關中斷帶來的風險，並確保能夠獲得滿足臨床需求的關鍵器械型號。

對終端用戶環境、藥物類型、通路、球囊尺寸、長度和塗層技術等因素對臨床應用的影響進行分段分析

細分市場分析揭示了不同的臨床環境和產品特性如何影響臨床環境中設備的選擇和使用模式。就終端用戶環境而言，門診手術中心和醫院的手術量、人員配備模式和資金限制各不相同，這促使醫療機構優先選擇一次性技術或投資於更有限的專業庫存。同樣，紫杉醇和Sirolimus藥物類型之間的差異也會影響臨床決策，這取決於當地的安全性認知、臨床醫生的熟悉程度以及對特定病變亞群療效的預期。直銷和批發分銷管道的選擇對營運具有重要意義。直銷往往有利於促進更緊密的商業臨床合作和產品培訓，而批發分銷則能提供更廣泛的覆蓋率和庫存整合。

從區域觀點檢視美洲、歐洲、中東和非洲以及亞太市場的臨床、監管、報銷和供應鏈的考量因素

區域趨勢對周邊藥物釋放型球囊系統的監管路徑、報銷機制和臨床應用率有顯著影響。在美洲，手術創新往往與既定的介入治療模式、醫院主導的採購流程以及複雜的報銷環境密切相關。這種報銷環境會根據支付方的接受程度和編碼的清晰度，促進或限制其應用。歐洲、中東和非洲地區的監管和採購環境各不相同，國家和地區層級的衛生技術評估（HTA）框架會影響引進週期。本地的生產和分銷協議會對市場進入和定價動態產生重大影響。亞太地區涵蓋了從高度監管的成熟市場到快速發展的醫療基礎設施，市場類型多樣化。在許多地區，對成本效益高的治療方法和高容量手術能力的關注，決定了器械的選擇和臨床應用的速度。

從公司觀點對血管器材產業的策略聯盟、產品創新、製造韌性和競爭差異化進行深入分析

該專業領域的公司正透過漸進式產品開發、策略聯盟和週期性整合相結合的方式，在創新和規模化之間尋求平衡。大型醫療設備製造商的產品系列優先考慮成熟的平台技術和廣泛的商業性覆蓋，而規模較小的專業公司則專注於改進特定特性，例如刻痕元件幾何形狀、藥物塗層穩定性以及新型沉積方法。醫療設備製造商擴大與契約製造組織 (CMO) 合作，以加快產品改進週期並控制與檢驗塗層製程相關的資本密集度。

為領導者提供建議，以加快臨床應用、增強供應鏈韌性、協調監管方法並維持血管器械領域的創新。

為了推動周邊血管刻痕藥物釋放型球囊技術的持續應用，產業領導者應優先考慮整合臨床檢驗、供應保障和監管前瞻性的協作模式。首先，各機構應投入資源進行嚴格的操作培訓和結果追蹤，以檢驗該設備在特定患者群體中的有效性。這將有助於增強臨床醫師的信心，並促進內部達成共識，推動該設備的推廣應用。其次，採購和供應鏈團隊應努力實現籌資策略多元化，並制定緊急時應對計畫，以確保關鍵設備配置的供應，同時最大限度地降低地緣政治因素和關稅帶來的干擾。

一套清晰的調查方法，明確規定了資料來源、相關人員訪談、證據綜合、檢驗過程以及所適用的倫理標準。

本分析的調查方法整合了多方面的證據，以得出關於醫療設備現狀的一致且可驗證的檢驗。主要證據來自對臨床負責人、採購經理和監管專家的結構化訪談，並輔以醫療設備附加檔審查和已發布的監管文件。二級資訊來源包括同行評審的臨床文獻、臨床學會指南和手術最佳實踐出版物，以確保對醫療設備性能的討論基於當前的臨床經驗和標準。

簡明扼要地總結了臨床、技術、監管和商業性觀點，以指南策略決策和未來研究重點。

這項綜合分析結合了臨床、技術、監管和商業性觀點，旨在為周邊刻痕藥物釋放型洗脫球囊系統的相關人員提供實際決策依據。臨床證據和外科醫生經驗表明，在某些情況下，將機械刻痕與局部藥物輸送相結合可以帶來顯著的手術獲益，尤其是在易發生彈性回縮和血管再阻塞的解剖結構中。塗層化學和可控刻痕機制的技術進步縮小了性能與操作性之間的傳統差距。同時，監管機構日益關注，凸顯了可靠的安全性數據和上市後監測數據的重要性。

目錄

第1章：序言

第2章調查方法

• 研究設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查前提
• 調查限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會地圖
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 周邊血管藥物釋放型球囊擴張導管市場（依藥物類型分類）

• 紫杉醇
• Sirolimus

9. 周邊血管藥物釋放型球囊擴張導管市場（依球囊長度分類）

• 超過 40 毫米
• 21～40mm
• 20毫米或更小

10. 周邊血管藥物釋放型球囊擴張導管市場（依塗層技術分類）

• 雙層型
• 不含聚合物
• 單層

11. 依最終用戶分類的周邊藥物藥物釋放型球囊擴張導管市場

• 門診手術中心
• 醫院

12. 周邊藥物藥物釋放型球囊擴張導管市場（依地區分類）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

13. 周邊藥物藥物釋放型球囊擴張導管市場（依組別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 各國外周藥物藥物釋放型球囊擴張導管市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

15. 美國周邊藥物釋放型球囊擴張導管市場

第16章 中國周邊血管藥物釋放型球囊擴張導管市場

第17章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Aachen Resonance GmbH
• Abbott Laboratories
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• BrosMed Medical Co., Ltd.
• Cardionovum GmbH
• Concept Medical Research Private Limited
• Cook Medical LLC
• Cordis Corporation
• Eurocor GmbH
• iVascular, SLU
• Koninklijke Philips NV
• MedAlliance SA
• Medtronic plc
• Meril Life Sciences Private Limited
• MicroPort Scientific Corporation
• Teleflex Incorporated
• Terumo Corporation

The Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market was valued at USD 863.01 million in 2025 and is projected to grow to USD 949.96 million in 2026, with a CAGR of 10.69%, reaching USD 1,757.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 863.01 million
Estimated Year [2026]	USD 949.96 million
Forecast Year [2032]	USD 1,757.84 million
CAGR (%)	10.69%

Comprehensive introduction to peripheral scoring drug-eluting balloon dilation catheters, their clinical role, technological foundations, and stakeholder impacts

Peripheral scoring drug-eluting balloon dilation catheters occupy a distinct intersection of interventional technique and targeted pharmacologic delivery, offering clinicians an alternative strategy for addressing complex peripheral arterial disease. These devices combine mechanical plaque modification with local antiproliferative drug administration to improve vessel preparation and support sustained patency, particularly in challenging lesions where plain balloon angioplasty has limitations. As clinical teams refine patient selection and procedural workflows, these catheters increasingly feature in multidisciplinary conversations involving vascular surgeons, interventional radiologists, and catheterization laboratory staff.

From a technological standpoint, the devices represent a convergence of advances in balloon design, coating science, and delivery precision. Innovations in scoring elements seek to optimize controlled plaque fracture while minimizing vessel trauma, and drug-eluting formulations aim to suppress neointimal hyperplasia at the site of injury. Together, these attributes influence procedural planning, post-procedure management, and the expectations of long-term device performance. Consequently, stakeholders across clinical, procurement, and regulatory functions must weigh clinical efficacy, procedural complexity, and device characteristics when considering adoption and integration into care pathways.

Analysis of transformative shifts reshaping peripheral scoring drug-eluting balloon use including procedural techniques, material science, and clinical pathways

The landscape for peripheral scoring drug-eluting balloon therapy is experiencing a set of transformative shifts driven by clinical evidence, materials science, and procedural optimization. Clinically, growing experience with complex lesion subsets has sharpened understanding of when scoring mechanisms add value relative to conventional angioplasty, and when drug elution provides measurable benefit in limiting restenosis. As a result, protocol development and operator technique have evolved, emphasizing lesion preparation, appropriate balloon sizing, and post-dilation assessment using intravascular imaging where available.

Technological progress in coating chemistries and deposition techniques has improved drug transfer efficiency and reduced downstream particulate concerns, influencing regulatory scrutiny and hospital procurement decisions. Concurrently, manufacturing advances and supply chain rationalization have enabled more consistent product quality and smaller-batch innovation from specialist manufacturers. Taken together, these forces are shifting the balance between standalone scoring balloons, drug-eluting variants, and hybrid approaches, prompting healthcare systems to revisit training, capital planning, and outcome measurement to ensure that device selection aligns with evolving standards of care.

Evaluation of the cumulative impact of United States tariffs in 2025 on peripheral scoring drug-eluting balloon supply chains, costs, and strategic sourcing

The introduction of United States tariffs in 2025 has introduced an additional strategic dimension for manufacturers, distributors, and health systems that rely on cross-border supply chains for peripheral vascular devices. While tariffs do not change the clinical profile of devices, they alter procurement calculus by affecting landed costs, supplier selection, and inventory strategies. In response, organizations are reassessing supplier diversity and logistical models to mitigate exposure to tariff-related disruptions and to preserve access to critical device variants that meet clinical needs.

Practically, procurement teams are undertaking scenario planning that considers alternative manufacturing footprints, nearshoring options, and tiered distribution agreements to sustain availability. Regulatory and compliance functions are coordinating with commercial teams to track tariff classifications and to ensure that device labeling and material disclosures meet customs requirements. For clinical operations, the primary implication is the potential need to validate new suppliers or device lots more frequently, and to update contracted pricing frameworks to reflect changes in total cost of ownership rather than unit price alone. Above all, the tariffs have underscored the value of supply chain transparency and proactive engagement across procurement, regulatory affairs, and clinical leadership.

Segmented insights on how end user environments, drug types, distribution routes, balloon sizes, lengths, and coating technologies shape clinical adoption

Segmentation analysis clarifies how different clinical environments and product characteristics shape device selection and utilization patterns across care settings. When considering end user environments, Ambulatory Surgical Center and Hospital settings each present distinct procedural volumes, staffing models, and capital constraints that influence whether a facility prioritizes single-use disposable technologies or invests in a narrower range of specialized inventory. Likewise, the distinction between Paclitaxel and Sirolimus drug types affects clinical decision-making based on local safety narratives, clinician familiarity, and perceived efficacy in specific lesion subsets. Distribution choices between Direct Sales and Wholesale Distributor channels have operational implications, where direct sales often facilitate tighter commercial-clinical collaboration and product training while wholesale distribution offers broader reach and inventory aggregation.

Device geometry further refines clinical deployment, as balloon diameter categorized as Above Four Mm or Up To Four Mm guides suitability for larger conduit vessels versus smaller distal targets, and length designations of Above Forty Mm, Twenty One To Forty Mm, and Up To Twenty Mm determine treatment strategies for focal versus long-segment disease. Coating technology differentiations-Dual Layer, Polymer Free, and Single Layer-affect drug delivery kinetics, surface interaction with blood elements, and handling characteristics during insertion and deployment. Taken together, these segmentation dimensions inform procurement bundles, clinician training programs, and the design of clinical studies that aim to demonstrate device performance across relevant use cases.

Regional perspectives examining clinical, regulatory, reimbursement, and supply chain considerations across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a strong influence on regulatory pathways, reimbursement mechanics, and clinical adoption rates for peripheral scoring drug-eluting balloon systems. In the Americas, procedural innovation often aligns with robust interventional practice patterns, hospital-based purchasing processes, and a complex reimbursement landscape that can either encourage or constrain use depending on payer acceptance and coding clarity. Europe, Middle East & Africa presents a heterogenous regulatory and procurement environment where national and regional health technology assessment frameworks drive adoption cycles, and where localized manufacturing or distributor arrangements can materially affect market access and pricing negotiation dynamics. Asia-Pacific encompasses diverse markets ranging from highly regulated mature systems to rapidly developing healthcare infrastructures; in many territories, emphasis on cost-effective interventions and high-volume procedural throughput shapes device selection and the pace of clinical uptake.

Across these regions, regulatory expectations for clinical evidence, post-market surveillance, and device labeling differ, which in turn shapes go-to-market strategies. Supply chain considerations vary with geographic concentration of manufacturing hubs, customs regimes, and logistical complexity, demanding differentiated sourcing tactics. Clinical training and investigator networks also display regional patterns, influencing the dissemination of best practices and the speed at which new device iterations achieve meaningful adoption within different healthcare ecosystems.

High-level company-focused insights on strategic partnerships, product innovation, manufacturing resilience, and competitive differentiation in vascular devices

Corporate behavior within this specialized segment reflects a mix of incremental product development, strategic partnerships, and periodic consolidation as companies seek to balance innovation with scale. Leading medical device manufacturers maintain portfolios that prioritize proven platform technologies and wide commercial reach, while smaller specialty firms focus on improving niche attributes such as scoring element geometry, drug-coating stability, or novel deposition methods. Collaboration between device firms and contract manufacturing organizations has increased to accelerate product iteration cycles and to manage capital intensity associated with validated coating processes.

Commercial strategies increasingly emphasize clinical evidence generation, real-world data collection, and clinician education to differentiate offerings in a crowded environment. Firms with strong distribution networks can rapidly deploy training and build procedural volume, whereas companies that invest in manufacturing resilience and robust quality systems are better positioned to respond to supply chain shocks. Additionally, partnerships that pair large-scale commercialization capability with nimble product development have emerged as a common path to scale innovations while ensuring regulatory and reimbursement alignment. Collectively, these trends illustrate how firms are adapting corporate strategy to address both clinical expectations and operational realities.

Recommendations for leaders to accelerate clinical adoption, strengthen supply resilience, align regulatory approaches, and sustain innovation in vascular devices

Industry leaders should prioritize a coordinated approach that aligns clinical validation, supply continuity, and regulatory foresight to drive sustainable adoption of peripheral scoring drug-eluting balloon technologies. First, organizations must invest in rigorous procedural training and outcomes tracking to validate device benefits within their specific patient populations, thereby building clinician confidence and facilitating internal consensus for adoption. Second, procurement and supply chain teams should diversify sourcing strategies and create contingency plans that minimize exposure to geopolitical and tariff-induced disruption while preserving access to critical device configurations.

In parallel, commercial and regulatory functions ought to collaborate on evidence generation that addresses payer concerns and supports favorable reimbursement dialogues. Companies should consider modular product portfolios that allow clinicians to match balloon diameter, length, and coating characteristics to lesion anatomy without excessive inventory burden. Finally, fostering cross-functional partnerships-linking clinical champions, engineering teams, and commercial leads-will accelerate iterative improvements, shorten feedback cycles, and help translate insights from the bedside into next-generation device enhancements and targeted commercialization plans.

Clear research methodology describing data sources, stakeholder interviews, evidence synthesis, validation processes, and applied ethical standards

The methodological approach underpinning this analysis integrates multiple lines of evidence to produce a coherent, verifiable perspective on the device landscape. Primary evidence was obtained through structured interviews with clinical operators, procurement managers, and regulatory specialists, supplemented by device labeling reviews and publicly available regulatory documentation. Secondary sources included peer-reviewed clinical literature, clinical society guidance, and procedural best-practice publications to ensure that device performance discussions are grounded in current clinical experience and standards.

Synthesis employed cross-validation techniques that compared interview insights with published evidence and manufacturer disclosures, and quality assurance steps included triangulating findings across data types to minimize bias. Ethical standards guided stakeholder engagement, ensuring voluntary participation and confidentiality where requested. Finally, interpretation prioritized actionable implications for clinical teams, manufacturers, and procurement leaders, with transparent notes on evidence limitations and areas where further primary investigation would add value.

Concise conclusion synthesizing clinical, technological, regulatory, and commercial perspectives to inform strategic decisions and future research priorities

This synthesis brings clinical, technological, regulatory, and commercial perspectives together to inform practical decision-making for stakeholders involved with peripheral scoring drug-eluting balloon systems. Clinical evidence and operator experience point to scenarios where combined mechanical scoring and localized drug delivery can provide meaningful procedural advantages, particularly in anatomies prone to elastic recoil or restenosis. Technological progress in coating chemistry and controlled scoring mechanisms has narrowed previous gaps in performance and handling, while evolving regulatory attention underscores the importance of robust safety and post-market surveillance data.

Commercially, procurement and supply considerations increasingly factor into device selection, with organizations seeking partners that demonstrate manufacturing reliability and responsive distribution models. Taken as a whole, the sector is maturing: incremental innovation is producing devices that better balance efficacy and deliverability, and stakeholders that align clinical protocols with evidence-based procurement strategies will be best positioned to realize patient and system-level gains. Further targeted research and real-world data collection will continue to refine clinical indications and inform cost-effective deployment strategies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Drug Type

• 8.1. Paclitaxel
• 8.2. Sirolimus

9. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Balloon Length

• 9.1. Above Forty Mm
• 9.2. Twenty One To Forty Mm
• 9.3. Up To Twenty Mm

10. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Coating Technology

• 10.1. Dual Layer
• 10.2. Polymer Free
• 10.3. Single Layer

11. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by End User

• 11.1. Ambulatory Surgical Center
• 11.2. Hospital

12. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market

16. China Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Aachen Resonance GmbH
• 17.6. Abbott Laboratories
• 17.7. B. Braun Melsungen AG
• 17.8. Becton, Dickinson and Company
• 17.9. BIOTRONIK SE & Co. KG
• 17.10. Boston Scientific Corporation
• 17.11. BrosMed Medical Co., Ltd.
• 17.12. Cardionovum GmbH
• 17.13. Concept Medical Research Private Limited
• 17.14. Cook Medical LLC
• 17.15. Cordis Corporation
• 17.16. Eurocor GmbH
• 17.17. iVascular, S.L.U.
• 17.18. Koninklijke Philips N.V.
• 17.19. MedAlliance SA
• 17.20. Medtronic plc
• 17.21. Meril Life Sciences Private Limited
• 17.22. MicroPort Scientific Corporation
• 17.23. Teleflex Incorporated
• 17.24. Terumo Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY ABOVE FORTY MM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY ABOVE FORTY MM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY ABOVE FORTY MM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY TWENTY ONE TO FORTY MM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY TWENTY ONE TO FORTY MM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY TWENTY ONE TO FORTY MM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY UP TO TWENTY MM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY UP TO TWENTY MM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY UP TO TWENTY MM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DUAL LAYER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DUAL LAYER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DUAL LAYER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SINGLE LAYER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SINGLE LAYER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SINGLE LAYER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 38. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 39. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 40. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 41. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 42. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 44. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 45. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 46. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 47. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 48. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 49. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 50. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 51. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 52. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 57. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 59. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 60. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 61. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 62. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 64. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 65. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 66. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 67. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 69. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 70. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 71. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 72. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 80. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 81. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 82. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 83. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 84. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 85. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 86. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 87. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 88. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 89. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 90. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 91. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 92. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 93. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 95. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 96. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 97. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 98. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 100. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 101. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 102. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 103. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 104. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 105. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 106. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 107. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 110. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 111. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 112. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 113. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 114. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 115. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 116. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 117. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 118. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)